Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313482865> ?p ?o ?g. }
- W4313482865 endingPage "e2249370" @default.
- W4313482865 startingPage "e2249370" @default.
- W4313482865 abstract "Prevalent use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors, compared with those that do not stimulate these receptors, has been associated with a lower risk of dementia. However, previous studies were limited by inclusion of individuals with prevalent hypertension and a history of antihypertensive use prior to the start of the study, which can introduce bias.To examine the association of new use of antihypertensive medication regimens that stimulate vs inhibit type 2 and 4 angiotensin II receptors with Alzheimer disease and related dementias (ADRD) among Medicare beneficiaries.This cohort study was conducted among 57 773 Medicare fee-for-service beneficiaries (January 1, 2006, through December 31, 2018) aged 65 years or older with incident hypertension. Data analysis was conducted from January 1 through June 30, 2022.Initiation of antihypertensive medication regimens that stimulate or inhibit type 2 and 4 angiotensin II receptors, or mixed regimens (both stimulating and inhibiting), with the time-dependent measure being each 30-day interval.The primary outcome was time to first occurrence of ADRD (Centers for Medicare & Medicaid Services Chronic Conditions Data Warehouse definition). Cox proportional hazards regression modeling with time-dependent variables was performed to estimate the association between time-dependent treatment groups and time to ADRD, after adjusting for sociodemographic and clinical characteristics.The sample included 57 773 Medicare beneficiaries (36 348 women [62.9%]; mean [SD] age, 73.8 [6.3] years; 2954 [5.1%] Black, 1545 [2.7%] Hispanic; 50 184 [86.9%] White, and 3090 [5.4%] Other individuals [the Other category included individuals of American Indian, Asian, other, or unknown race and ethnicity]). During a median of 6.9 years (IQR, 4.7-9.3 years) of follow-up, the unadjusted incidence density rate of ADRD was 2.2 cases per 100 person-years (95% CI, 2.1-2.4 cases per 100 person-years) for the group receiving regimens that stimulate type 2 and 4 angiotensin II receptors compared with 3.1 cases per 100 person-years (95% CI, 3.0-3.2 cases per 100 person-years) for the group receiving regimens that inhibit type 2 and 4 angiotensin II receptors and 2.7 cases per 100 person-years (95% CI, 2.6-2.9 cases per 100 person-years) for the group receiving mixed treatment regimens. In adjusted Cox proportional hazards regression modeling, stimulating treatment was associated with a statistically significant 16% reduction in the hazard of ADRD compared with inhibiting treatment (hazard ratio, 0.84; 95% CI, 0.79-0.90). Mixed regimen use was also associated with reduced hazards of ADRD compared with the inhibiting group (hazard ratio, 0.90; 95% CI, 0.84-0.96).This cohort study of Medicare beneficiaries suggests that use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors was associated with lower risk of ADRD compared with antihypertensive medications that inhibit these receptors. Confirmation is needed in a randomized trial." @default.
- W4313482865 created "2023-01-06" @default.
- W4313482865 creator A5008785679 @default.
- W4313482865 creator A5039182059 @default.
- W4313482865 creator A5042854532 @default.
- W4313482865 creator A5084279534 @default.
- W4313482865 date "2023-01-04" @default.
- W4313482865 modified "2023-10-02" @default.
- W4313482865 title "Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries" @default.
- W4313482865 cites W1412300033 @default.
- W4313482865 cites W1934443959 @default.
- W4313482865 cites W1981731922 @default.
- W4313482865 cites W1995817686 @default.
- W4313482865 cites W1998052464 @default.
- W4313482865 cites W2006922743 @default.
- W4313482865 cites W2010627562 @default.
- W4313482865 cites W2033254342 @default.
- W4313482865 cites W2034471139 @default.
- W4313482865 cites W2035141165 @default.
- W4313482865 cites W2044409604 @default.
- W4313482865 cites W2052039715 @default.
- W4313482865 cites W2058850221 @default.
- W4313482865 cites W2065143832 @default.
- W4313482865 cites W2067756041 @default.
- W4313482865 cites W2072749612 @default.
- W4313482865 cites W2098429613 @default.
- W4313482865 cites W2109764696 @default.
- W4313482865 cites W2143549199 @default.
- W4313482865 cites W2145875145 @default.
- W4313482865 cites W2324980061 @default.
- W4313482865 cites W2792021977 @default.
- W4313482865 cites W2914038374 @default.
- W4313482865 cites W2974923570 @default.
- W4313482865 cites W2981048659 @default.
- W4313482865 cites W3046275966 @default.
- W4313482865 cites W3047109959 @default.
- W4313482865 cites W3097116649 @default.
- W4313482865 cites W3119248501 @default.
- W4313482865 cites W4210272258 @default.
- W4313482865 cites W4229054431 @default.
- W4313482865 cites W4234911643 @default.
- W4313482865 cites W4248225996 @default.
- W4313482865 cites W4256630164 @default.
- W4313482865 doi "https://doi.org/10.1001/jamanetworkopen.2022.49370" @default.
- W4313482865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36598787" @default.
- W4313482865 hasPublicationYear "2023" @default.
- W4313482865 type Work @default.
- W4313482865 citedByCount "3" @default.
- W4313482865 countsByYear W43134828652023 @default.
- W4313482865 crossrefType "journal-article" @default.
- W4313482865 hasAuthorship W4313482865A5008785679 @default.
- W4313482865 hasAuthorship W4313482865A5039182059 @default.
- W4313482865 hasAuthorship W4313482865A5042854532 @default.
- W4313482865 hasAuthorship W4313482865A5084279534 @default.
- W4313482865 hasBestOaLocation W43134828651 @default.
- W4313482865 hasConcept C126322002 @default.
- W4313482865 hasConcept C127413603 @default.
- W4313482865 hasConcept C160735492 @default.
- W4313482865 hasConcept C162324750 @default.
- W4313482865 hasConcept C27016395 @default.
- W4313482865 hasConcept C2776534028 @default.
- W4313482865 hasConcept C2779134260 @default.
- W4313482865 hasConcept C2779483572 @default.
- W4313482865 hasConcept C2780645631 @default.
- W4313482865 hasConcept C2910553456 @default.
- W4313482865 hasConcept C50382708 @default.
- W4313482865 hasConcept C50522688 @default.
- W4313482865 hasConcept C71924100 @default.
- W4313482865 hasConcept C72563966 @default.
- W4313482865 hasConcept C74909509 @default.
- W4313482865 hasConcept C78519656 @default.
- W4313482865 hasConcept C84393581 @default.
- W4313482865 hasConceptScore W4313482865C126322002 @default.
- W4313482865 hasConceptScore W4313482865C127413603 @default.
- W4313482865 hasConceptScore W4313482865C160735492 @default.
- W4313482865 hasConceptScore W4313482865C162324750 @default.
- W4313482865 hasConceptScore W4313482865C27016395 @default.
- W4313482865 hasConceptScore W4313482865C2776534028 @default.
- W4313482865 hasConceptScore W4313482865C2779134260 @default.
- W4313482865 hasConceptScore W4313482865C2779483572 @default.
- W4313482865 hasConceptScore W4313482865C2780645631 @default.
- W4313482865 hasConceptScore W4313482865C2910553456 @default.
- W4313482865 hasConceptScore W4313482865C50382708 @default.
- W4313482865 hasConceptScore W4313482865C50522688 @default.
- W4313482865 hasConceptScore W4313482865C71924100 @default.
- W4313482865 hasConceptScore W4313482865C72563966 @default.
- W4313482865 hasConceptScore W4313482865C74909509 @default.
- W4313482865 hasConceptScore W4313482865C78519656 @default.
- W4313482865 hasConceptScore W4313482865C84393581 @default.
- W4313482865 hasIssue "1" @default.
- W4313482865 hasLocation W43134828651 @default.
- W4313482865 hasLocation W43134828652 @default.
- W4313482865 hasLocation W43134828653 @default.
- W4313482865 hasOpenAccess W4313482865 @default.
- W4313482865 hasPrimaryLocation W43134828651 @default.
- W4313482865 hasRelatedWork W2056961093 @default.
- W4313482865 hasRelatedWork W2081265618 @default.
- W4313482865 hasRelatedWork W2145059764 @default.